Integrum AB (publ) (INTEG_B) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Integrum Ab Class B.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:03.937 Hello and welcome to today's episode of Integrum, which will be reporting the second 00:00:03.937 -- 00:00:07.121 quarter of 2025. After the presentation, we will have a Q&A session. 00:00:07.121 -- 00:00:11.768 If you have any questions for the company, you can send them in the form to the right. 00:00:11.768 -- 00:00:13.768 With 00:00:14.111 -- 00:00:17.857 that said, I'll hand over to Martin and Louise. 00:00:17.857 -- 00:00:24.504 Thank you, Ludvig, and welcome to our second quarter of the 25-26 business 00:00:24.547 -- 00:00:28.229 year. A short introduction to the company. 00:00:28.229 -- 00:00:33.317 Integrum is a pharmaceutical company. We are Swedish and we operate in 00:00:33.317 -- 00:00:38.565 Gothenburg. We have at least two markets in Europe and our primary market 00:00:38.565 -- 00:00:43.793 in the USA, where we also have a sales and marketing 00:00:43.793 -- 00:00:49.121 office with about 10 people. We have been active since 1998, but have 00:00:49.121 -- 00:00:52.864 been commercial a little more since 2020. 00:00:55.567 -- 00:01:00.612 Vi förändrar amputerade människors liv. Freedom and mobility for 00:01:00.612 -- 00:01:06.796 every person är vår ambition. Det är det som leder vårt arbete framåt. 00:01:06.799 -- 00:01:11.944 Vi opererar i en marknad som är stor. Cirka 3,9 00:01:11.944 -- 00:01:15.728 miljoner människor i Europa och USA är amputerade. 00:01:15.728 -- 00:01:18.951 Varav ungefär 350 000 00:01:18.951 -- 00:01:22.793 amputerade tillkommer i Europa. 00:01:23.731 -- 00:01:28.393 Our delivery in our system 00:01:28.796 -- 00:01:30.796 consists 00:01:30.918 -- 00:01:33.498 of an implant, 00:01:34.061 -- 00:01:38.843 an abatement that is 00:01:40.787 -- 00:01:42.449 a pillar 00:01:42.449 -- 00:01:45.790 of...